The form is not published.

Heading

The FLF 2025 Global Patient Survey – what did we learn?  

The FLF 2025 Global Patient Survey – what did we learn?  

In October 2025, we conducted the FLF’s annual Global Patient Survey to better understand the challenges, concerns, and priorities of ...
/
Joanne's Story

Joanne’s Story

I was on a lunch break at work and had gone for a short walk with my friend and received ...
/
What treatment should I start with?

Science Simplified – What Treatment Should I Start With?

What is the best first treatment for follicular lymphoma? We break down current standards, new research from ASH 2025, and ...
/
Tazemetostat in Follicular Lymphoma: What Patients Need to Know After the Recent Market Withdrawal

Tazemetostat in Follicular Lymphoma: What Patients Need to Know After the Recent Market Withdrawal

On 9th March came the announcement that tazemetostat (Tazverik) is being voluntarily withdrawn worldwide. Ipsen, the company that markets tazemetostat, ...
/
Epcoritamab Approved for Relapsed or Refractory Follicular Lymphoma on the NHS in England, Wales and Northern Ireland

Epcoritamab Approved for Relapsed or Refractory Follicular Lymphoma on the NHS in England, Wales and Northern Ireland

NICE has approved epcoritamab (Tepkinly) on the NHS for adults in England, Wales and Northern Ireland with relapsed or refractory ...
/
Celebrating the Women Researchers Driving Progress in Follicular Lymphoma Research 

Celebrating the Women Researchers Driving Progress in Follicular Lymphoma Research 

This International Women’s Day the FLF and our global community are proud to celebrate and highlight the exceptional women whose ...
/